The newest addition to A Breath of Hope’s Animated Patient Guide to Lung Cancer is here! We GO LIVE today with Common Biomarkers: Understanding Your Lung Cancer Mutation found at youandlungcancer.com.
With a focused approach to understanding common mutations, A Breath of Hope empowers patients to participate in decisions about their care. This new resources includes learning modules on the below mutations.
EGFR
KRAS
ALK, BRAF, ROS1, HER2, MET
IMMUNOTHERAPY with PD1 and PD-L1
Since its inception in November of 2017, A Breath of Hope’s literacy-based online patient education resource has drawn 1.4 million visits from 130 countries. Based on surveys, most visitors are patients and caregivers, with the next leading visitor group being providers. This patient education resource is designed to overcome patient literacy challenges and provides easy-to-understand education for different learning styles. Metrics are tracked to ensure learning takes place.
Our overarching goal is to improve health outcomes by reducing the anxiety that comes with limited knowledge and empowering patients to participate in decisions about their care.
Today, we are thrilled to offer lung cancer patients worldwide a chance to better understand precision medicine and specifically, their own tumor’s mutations and treatment options. This new module provides a deep dive into understanding the importance of precision medicine, common biomarkers, and the immunotherapy and targeted therapies available today – all leading to improved patient outcomes and survival.
A special thank you to our faculty experts, Dr. Joe Leach, Allina Health, and Dr. Naomi Fujioka, University of Minnesota. To view their videos, visit YouandLungCancer.com expert videos and navigate to module 6 – “Common Biomarkers in NSCLC”.
Our thanks to our primary educational partners, Bristol-Myers Squibb, Merck, Novartis, and Pfizer, and another thank you to Foundation Medicine for their support grant.
